Getinge Receives 510(k) Clearance for Servo-air® Mechanical Ventilator

My Subscriptions

Payment Confirmation

Transaction Failed

Your transaction failed, please try again or contact site support.

US Food & Drug Administration (FDA) clears Servo-air® mechanical ventilator for use with adult and pediatric patients dependent on intensive care ventilation expanding upon the Servo family of products available in the United States for decades.

“FDA 510(k) clearance for Servo-air® mechanical ventilator will broaden our US offering with a turbine-driven ventilator,” says Eric Honroth, President, North America at Getinge. “The Getinge Servo platform holds a leadership position in the US marketplace, further expanding Getinge’s global ventilation business.”

Servo-air® is a high performing ventilator intended for adult and pediatric patients and includes both Invasive and Non-Invasive (NIV) ventilation modes, including High Flow Therapy and Servo Compass options. Various modes allow clinicians to adapt and personalize ventilation to the patient and situation.

Honroth adds, “Servo-air has the same proven easy to use interface with the same context-based guidance as the Servo-u ventilator.”

Servo-air is turbine-driven and independent from wall gas that allows for powerful, uninterrupted, quiet ventilation benefitting the intensive care patient. Servo-air is ideally suited for intra-hospital transport, intermediary, or intensive care. Dual, hot-swappable batteries allow set up anywhere in the intensive care unit with powerful performance and optimal endurance.

Mechanical ventilation is a key component in the ongoing fight against COVID-19. “In partnership with intensive care clinicians, Getinge’s Servo-air can help save lives in the US market,” Honroth concludes.

Servo-air is expected to be available in the US in late 2020.

spot_img

DON'T MISS

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.